SHOC1: Key Regulator of Cell-Cell Adhesion and Potential Drug Target

Target Name: SHOC1

NCBI ID: G158401

SHOC1

SHOC1: Key Regulator of Cell-Cell Adhesion and Potential Drug Target

SHOC1 (short for SHO domain-containing 1) is a protein that is expressed in a variety of tissues and cells throughout the body. It is a key regulator of cell-cell adhesion, which is the process by which cells stick together to form tissues and organs.

SHOC1 has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions and interactions with other proteins have been extensively studied, and its potential as a drug target continue to attract research interest.

One of the key functions of SHOC1 is its role in cell-cell adhesion. SHOC1 is a member of the Shoc family of proteins, which are known for their ability to regulate cell-cell adhesion. This family of proteins includes other well-known proteins, such as SHOC2 and SHOC3, which are also involved in cell-cell adhesion.

SHOC1 functions by forming a complex with other proteins, including the transcription factor NF-kappa-B. This complex helps to regulate the expression of genes that are involved in cell-cell adhesion, as well as other processes that are important for cell growth and survival.

In addition to its role in cell-cell adhesion, SHOC1 is also involved in a number of other processes that are important for cell growth and development. For example, it is involved in the regulation of cell proliferation, and it has been shown to play a role in the development and progression of cancer.

SHOC1 has also been identified as a potential biomarker for a number of diseases. For example, SHOC1 has been shown to be overexpressed in a variety of cancer tissues, and it has been used as a biomarker for the diagnosis and prognosis of breast cancer.

In addition to its potential as a drug target and biomarker, SHOC1 is also of interest to researchers as a potential therapeutic target. For example, SHOC1 has been shown to be involved in a number of processes that are important for cell growth and survival, and drugs that can inhibit its activity may be effective in treating a variety of diseases.

Overall, SHOC1 is a protein that has important functions in cell growth and development, and it is of interest as a potential drug target and biomarker for a variety of diseases. Further research is needed to fully understand its mechanisms of action and its potential as a therapeutic target.

Protein Name: Shortage In Chiasmata 1

Functions: ATPase required during meiosis for the formation of crossover recombination intermediates (By similarity). Binds DNA: preferentially binds to single-stranded DNA and DNA branched structures (PubMed:29742103). Does not show nuclease activity in vitro, but shows ATPase activity, which is stimulated by the presence of single-stranded DNA (PubMed:29742103). Plays a key role in homologous recombination and crossing-over in meiotic prophase I in male and female germ cells (By similarity). Required for proper synaptonemal complex assembly and homologous chromosome pairing (By similarity). Requiref for recruitment TEX11 and MSH4 to recombination intermediates (By similarity)

The "SHOC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SHOC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets